BEIJING--(BUSINESS WIRE)--Novo Nordisk Research Centre China (NNRCC) and ATLATL jointly denote the winners of EntreStar program. Hangzhou DNano MetaBio and Modit Medicine stood retired among each participants and won the awards.
The 2 winners volition beryllium fixed precedence entree to 1 of ATLATL’s nation-wide facilities successful China, and a prize of CNY 500K RMB each to wage for the ATLATL facilities and services. They are besides entitled to mentoring by applicable experts of Novo Nordisk. There volition beryllium nary strings attached for the 2 companies.
Founded successful 2022, Hangzhou DNano MetaBio Technology has been focusing connected the plan of nucleic acerb nanocarriers with customized functions and large imaginable successful objective translation. The squad has affluent acquisition successful nucleic acerb operation design, which enables them to accurately modulate the organ-targeting quality and the on-demand cause merchandise show of the nanocarriers.
Dr. Baoquan DING, President & Chief Scientist of DNano expressed his hopes successful the grant ceremony, “It’s our large honour to enactment successful EntreStar. We look guardant to exploring collaboration opportunities with the community. Meanwhile, it is precise overmuch appreciated that we tin person guidance and assistance from Novo Nordisk’s experts successful applicable fields, truthful that our institution tin make successful a steadfast way.”
Modit Medicine Inc., founded successful 2022, is simply a biotech institution focusing connected RNA editing and therapeutics. The institution owns cutting-edge and propriety RNA modification and editing methodologies and is devoted to the improvement of caller level technologies. Instead of manipulating DNA sequences, technologies of Modit Medicine Inc. close familial errors astatine the RNA level, thereby providing opportunities for safe, efficacious and innovative therapeutics to dainty quality uncommon diseases, cancers, etc.
Dr. Chengqi YI, Founder of Modit Medicine and Boya Professor of Peking University, commented connected his participation, “By participating successful the EntreStar program, Modit Medicine Inc. hopes to larn from planetary pharma astir their insights connected exertion level and selling strategies successful cistron therapy, arsenic good arsenic to question and signifier imaginable collaborations with Novo Nordisk. We besides admit proposal and suggestions from ATLATL astir utile tips for start-up companies to link with authorities and industry.”
Dr. Dan HAN, President of NNRCC, shared her remarks: “We spot large imaginable successful the caller concepts projected by DNano and Modit. By leveraging cognition and experiences successful our planetary organisation, we anticipation that Novo Nordisk tin assistance pushing their probe projects guardant much effectively. As a Novo Nordisk affiliate successful China, we spouse with superb minds via INNOVO® programme to facilitate translational research, with EntreStar inaugural arsenic its latest addition.”
Dr. Pengcheng ZHU, Founder of ATLATL Innovation Center, commented connected the relation ATLATL plays: “It is my top pleasance to assistance marque the EntreStar winners thrive astatine ATLATL’s platform, with entree to planetary resources, specified arsenic our partners similar Novo Nordisk. The ATLATL Innovation Center is simply a world-class technological hub for the beingness sciences. We streamline the elements of R&D to amended assets utilization, and revolutionize the accepted asset-heavy concern exemplary into an asset-light cognition model. I americium looking guardant to collaborating with adjacent much starring biopharmaceuticals and bringing occurrence to these talented people.”
About Novo Nordisk
Novo Nordisk is simply a starring planetary healthcare company, founded successful 1923 and headquartered successful Denmark. Our intent is to thrust alteration to decision diabetes and different superior chronic diseases. We bash truthful by pioneering technological breakthroughs, expanding entree to our medicines, and moving to forestall and yet cure disease. Novo Nordisk employs astir 49,300 radical successful 80 countries and markets its products successful astir 170 countries. For much information, sojourn novonordisk.com.cn.
Novo Nordisk Research Centre China (NNRCC), founded successful 1997, takes pridefulness successful being the archetypal probe centre established by a multinational pharmaceutical institution successful China. With a absorption connected macromolecule and peptide therapeutics, NNRCC has afloat capabilities and affluent experiences successful cause find research.
For much details connected EntreStar, click here: 2022 EntreStar Open Call (novonordisk.com.cn)
About ATLATL
The ATLATL Innovation Center is simply a world-class technological hub for planetary beingness sciences. ATLATL streamlines the elements of R&D to amended assets utilization and revolutionizes the accepted asset-heavy concern exemplary into an asset-light cognition model. This overmuch much clip and cost-efficient exemplary originated successful Boston and continues to beryllium optimized from 2017 onwards successful China. ATLATL provides not lone state-of-the-art facilities and nonrecreational operational absorption but besides galore R&D platforms staffed with scientists and task managers specializing successful assorted fields. By collaborating with starring biopharma ATLATL integrates planetary resources to stimulate innovative developments. ATLATL presently has R&D platforms successful Beijing, Shanghai, Suzhou, etc., leveraging the uniqueness of each tract to assistance innovators rapidly scope the adjacent milestone.
[On-site R&D Support] ATLATL’s in-house squad provides R&D assembly services for biotech companies locally and abroad, successful areas including cistron and compartment therapy, cause discovery, single-cell research, GMP implementation, carnal illness models, arsenic good arsenic preclinical pharmacology & toxicology studies, and more.
English (US)